Old Web
English
Sign In
Acemap
>
authorDetail
>
Marianne van Vugt
Marianne van Vugt
Merck & Co.
Medicine
Melanoma
Immunogenicity
Pembrolizumab
Antibody
3
Papers
23
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Pharmacokinetics and Pharmacodynamics of the BACE1 Inhibitor Verubecestat (MK‐8931) in Healthy Japanese Adults: A Randomized, Placebo‐Controlled Study
2019
Clinical Pharmacology & Therapeutics
K. Chris Min
Marissa Dockendorf
John Palcza
Jack Tseng
Lei Ma
Julie A. Stone
Huub-Jan Kleijn
Peter Hodsman
Kazuko Masuo
Michael Tanen
Matthew D. Troyer
Marianne van Vugt
Mark S. Forman
Show All
Source
Cite
Save
Citations (8)
Immunogenicity of pembrolizumab (pembro) in patients (pts) with advanced melanoma (MEL) and non-small cell lung cancer (NSCLC): Pooled results from KEYNOTE-001, 002, 006, and 010.
2016
Journal of Clinical Oncology
Marianne van Vugt
Rik de Greef
Tomoko Freshwater
Eric Mangin
Frank van Aarle
Anna Kondic
Show All
Source
Cite
Save
Citations (10)
Population pharmacokinetic (popPK) model of pembrolizumab (pembro; MK-3475) in patients (pts) treated in KEYNOTE-001 and KEYNOTE-002.
2015
Journal of Clinical Oncology
Tara C. Gangadhar
Janice M. Mehnert
Amita Patnaik
Omid Hamid
Matteo S. Carlino
F. Stephen Hodi
Christian U. Blank
Antoni Ribas
Caroline Robert
Anna Kondic
Malidi Ahamadi
Tomoko Freshwater
Rik de Greef
Marianne van Vugt
Gregory M. Lubiniecki
Scot Ebbinghaus
Soonmo Peter Kang
Adil Daud
Show All
Source
Cite
Save
Citations (5)
1